Catheter Precision Inc. (NYSE American: VTAK) reported increased hospital evaluations and approvals for its LockeT suture retention device as it entered the first quarter of 2026. The company recorded its highest revenue for the month of January and expanded into several international markets. Catheter Precision has also secured approvals for LockeT evaluations at additional high-volume centers in the United States, including institutions such as Johns Hopkins, University of Michigan, Beth Israel in Boston, Northside hospitals in Atlanta, and Scripps in Southern California. The company attributes adoption momentum to LockeT's operational efficiency, rapid staff onboarding, and cost-effectiveness, including support for same-day discharge and reduced bed rest. Catheter Precision continues to expand in the European market following CE Mark approval, aiming for further adoption throughout the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catheter Precision Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648498-en) on February 04, 2026, and is solely responsible for the information contained therein.